Literature DB >> 8054788

Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma.

H Dralle1, I Damm, G F Scheumann, J Kotzerke, E Kupsch, H Geerlings, R Pichlmayr.   

Abstract

Lymph node metastases have been proven to be the main prognostic factor in medullary thyroid carcinoma (MTC). This retrospective study was undertaken to evaluate the efficiency of two surgical techniques of regional lymph node dissection with regard to the normalization of pentagastrin-stimulated serum calcitonin level and patient survival: selective lymphadenectomy, i.e., the excision of macroscopically or microscopically involved lymph nodes, versus a systematic lymphadenectomy performed by the new technique of a compartment-oriented microdissection. From 1970 to 1990, 82 patients with sporadic (n = 57) and hereditary (n = 25) MTC underwent a total of 142 operations including 63 selective lymphadenectomies and, since 1986, 35 systematic lymphadenectomies. The study revealed that in node-positive MTC the rate of interventions with a postoperative normalization of pentagastrin-stimulated serum calcitonin was higher after systematic lymphadenectomy (29.2%) than after selective lymphadenectomy (8.5%) (P < 0.01). The rate of patients undergoing repeat surgery due to a recurrence of MTC was 48% after selective lymphadenectomy and 10% after systematic lymphadenectomy. Survival was significantly better for patients after systematic versus selective lymphadenectomy (P < 0.005). This study thus emphasizes that systematic lymphadenectomy, using the technique of a compartment-oriented microdissection of cervicomediastinal lymph nodes, represents the preferred surgical treatment as well as the optimum technique in primary as well as secondary node-positive MTC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054788     DOI: 10.1007/bf02473391

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  32 in total

1.  Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma.

Authors:  L Troncone; V Rufini; G De Rosa; A Testa
Journal:  Henry Ford Hosp Med J       Date:  1989

2.  Evaluation of surgical results and prediction of prognosis in patients with medullary thyroid carcinoma by analysis of serum calcitonin levels.

Authors:  A Miyauchi; F Matsuzuka; K Kuma; S Takai; K Nakamoto; K Nakamura; S Nanjo; M Maeda
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

3.  Discordance between plasma calcitonin and tumor-cell mass in medullary thyroid carcinoma.

Authors:  D L Trump; G Mendelsohn; S B Baylin
Journal:  N Engl J Med       Date:  1979-08-02       Impact factor: 91.245

Review 4.  The value of lymph-node dissection in patients with differentiated thyroid cancer.

Authors:  S Noguchi; N Murakami
Journal:  Surg Clin North Am       Date:  1987-04       Impact factor: 2.741

5.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors:  J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

6.  Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid.

Authors:  E D Williams; C L Brown; I Doniach
Journal:  J Clin Pathol       Date:  1966-03       Impact factor: 3.411

7.  Localization and resection of clinically inapparent medullary carcinoma of the thyroid.

Authors:  J A Norton; J L Doppman; M F Brennan
Journal:  Surgery       Date:  1980-06       Impact factor: 3.982

Review 8.  Advances in the diagnosis and treatment of medullary thyroid carcinoma.

Authors:  L M Brunt; S A Wells
Journal:  Surg Clin North Am       Date:  1987-04       Impact factor: 2.741

9.  The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase.

Authors:  S M Lippman; G Mendelsohn; D L Trump; S A Wells; S B Baylin
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

10.  Medullary thyroid carcinoma: prognostic factors and treatment.

Authors:  P Rougier; C Parmentier; A Laplanche; M Lefevre; J P Travagli; B Caillou; M Schlumberger; J Lacour; M Tubiana
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-02       Impact factor: 7.038

View more
  35 in total

1.  Prognostic significance of disseminated tumor cells in the connective tissue of patients with medullary thyroid carcinoma.

Authors:  Oliver Gimm; Viola Heyn; Ulf Krause; Carsten Sekulla; Jörg Ukkat; Henning Dralle
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

2.  [Prophylactic thyroid surgery].

Authors:  A Frilling; F Weber
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

3.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

5.  Alternative surgical strategies in patients with sporadic medullary thyroid carcinoma: Long-term follow-up.

Authors:  Shi Hong Ma; Qin Jiang Liu; You Cheng Zhang; Rong Yang
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

6.  [Total thyroidectomy with lymph node dissection of the central compartment for node-positive, capsular invasive papillary thyroid cancer: video contribution].

Authors:  H Dralle; P Nguyen Thanh
Journal:  Chirurg       Date:  2014-10       Impact factor: 0.955

7.  Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Authors:  Olga Esik; Gábor Tusnády; Lajos Trón; András Boér; Zoltán Szentirmay; István Szabolcs; Károly Rácz; Erzsébet Lengyel; Judit Székely; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 8.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  [Surgery of thyroid carcinoma].

Authors:  H Dralle; K Lorenz; A Machens
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.